Tirzepatide Research Vial 5mg

Tirzepatide is a synthetic peptide analogue of the human glucose-dependent insulinotropic polypeptide (GIP) engineered as a dual agonist of both GIP and GLP-1 receptors. With equal binding affinity to native GIP, it uniquely activates both incretin pathways to produce synergistic effects on glucose homeostasis, appetite regulation, and energy metabolism. This 5mg lyophilized formulation is supplied in research-grade purity (≥98%) for laboratory investigations. The dual mechanism distinguishes tirzepatide from single-receptor agonists. GIP receptor activation complements GLP-1 signaling by enhancing insulin secretion in a glucose-dependent manner, promoting adipose tissue remodeling, and improving energy partitioning. The combined effect produces superior glycemic control and more pronounced body weight reduction compared to GLP-1 receptor agonists alone. Clinical data from the SURPASS (T2D) and SURMOUNT (obesity) trial programs provide extensive documentation of tirzepatide’s effects. SURMOUNT-1 demonstrated up to 22.5% mean body weight loss at 72 weeks in the 15mg dose cohort. Additional endpoints include significant improvements in HbA1c, fasting glucose, lipid profiles, and systolic blood pressure. This research material is intended for laboratory investigation purposes including in vitro receptor binding assays, cell culture studies, and preclinical research models. Not for human or veterinary use.